Profile
Fabrice Piu worked as a Director of Chemical Genomics at ACADIA Pharmaceuticals, Inc. and as a Vice President of Research & Preclinical Development at Otonomy, Inc. He holds a doctorate degree from École Normale Supérieure and undergraduate and graduate degrees from the University of Lyon.
Former positions of Fabrice Piu
| Companies | Position | End |
|---|---|---|
| OTONOMY | Chief Tech/Sci/R&D Officer | 2022-12-31 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Training of Fabrice Piu
| École Normale Supérieure | Doctorate Degree |
| University of Lyon | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Fabrice Piu
